Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy

Biochemical Journal

Volumn 461, Issue 1, 2014, Pages 1-13

  Yan, Ruiyang ^a   Hallam, Andrew ^a   Stockley, Peter G ^a   Boyes, Joan ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cancer; Nanomedicine; Oncogene addiction; RNAi delivery; Targeted therapy

Indexed keywords

BCR ABL PROTEIN; CYCLODEXTRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERFERON REGULATORY FACTOR 4; LIPOSOME; POLYMER; RNA; VIRUS VECTOR;

CANCER GENE THERAPY; CHEMICAL MODIFICATION; CHRONIC MYELOID LEUKEMIA; ENDOSOME; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS LIKE AGENT; ZETA POTENTIAL;

ANIMALS; GENE TARGETING; GENETIC THERAPY; HUMANS; NEOPLASMS; ONCOGENES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84902317646     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20140173     Document Type: Review

References (165)

1. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70 CrossRef PubMed (Pubitemid 30046295)
2. Luo, J., Solimini, N. L. and Elledge, S. J. (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 CrossRef PubMed
3. Rous, P. (1911) A sarcoma of the fowl transmissible by an agent from the tumor cells. J. Exp. Med. 13, 397-411 CrossRef PubMed
4. Baltimore, D. (1970) Viral RNA-dependent DNA polymerase: RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 226, 1209-1211 CrossRef PubMed
5. Temin, H. M. and Mizutani, S. (1970) RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226, 1211-1213 CrossRef PubMed
6. Wang, L. H., Duesberg, P. H., Kawai, S. and Hanafusa, H. (1976) Location of envelope-specific and sarcoma-specific oligonucleotides on RNA of Schmidt-Ruppin Rous sarcoma virus. Proc. Natl. Acad. Sci. U.S.A. 73, 447-451 CrossRef PubMed
7. Stehelin, D., Varmus, H. E., Bishop, J. M. and Vogt, P. K. (1976) DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260, 170-173 CrossRef PubMed
8. Knudson, A. G. (1971) Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U.S.A. 68, 820-823 CrossRef PubMed
9. Sherr, C. J. (2004) Principles of tumor suppression. Cell 116, 235-246 CrossRef PubMed
10. MacPherson, D. and Dyer, M. A. (2007) Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy. Cancer Res. 67, 7547-7550 CrossRef PubMed (Pubitemid 47281344)
11. Renan, M. J. (1993) How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog. 7, 139-146 CrossRef PubMed
12. Brummelkamp, T. R., Bernards, R. and Agami, R. (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247 CrossRef PubMed (Pubitemid 41043979)
13. Li, R. H., Yerganian, G., Duesberg, P., Kraemer, A., Willer, A., Rausch, C. and Hehlmann, R. (1997) Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells. Proc. Natl. Acad. Sci. U.S.A. 94, 14506-14511 CrossRef PubMed (Pubitemid 28041404)
14. Hahn, W. C. and Weinberg, R. A. (2002) Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2, 331-341 CrossRef PubMed (Pubitemid 37328946)
15. Weinstein, I. B. (2002) Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64 CrossRef PubMed
16. Weinstein, I. B. and Joe, A. (2008) Oncogene addiction. Cancer Res. 68, 3077-3080 CrossRef PubMed
17. Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W. M., Powell, J., Dave, S., Yu, X., Zhao, H. et al. (2008) IRF4 addiction in multiple myeloma. Nature 454, 226-231 CrossRef PubMed (Pubitemid 351969894)
18. Pelengaris, S., Littlewood, T., Khan, M., Elia, G. and Evan, G. (1999) Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3, 565-577 CrossRef PubMed (Pubitemid 29268440)
19. Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., Bishop, J. M. and Felsher, D. W. (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297, 102-104 CrossRef PubMed (Pubitemid 34743102)
20. Karlsson, A., Giuriato, S., Tang, F., Fung-Weier, J., Levan, G. and Felsher, D. W. (2003) Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 101, 2797-2803 CrossRef PubMed (Pubitemid 36857646)
21. Gunther, E. J., Moody, S. E., Belka, G. K., Hahn, K. T., Innocent, N., Dugan, K. D., Cardiff, R. D. and Chodosh, L. A. (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 17, 488-501 CrossRef PubMed (Pubitemid 36258763)
22. D'Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., Cox, J. D., Ha, S. I., Belka, G. K., Golant, A. et al. (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 7, 235-239 CrossRef PubMed (Pubitemid 32148492)
23. Solimini, N. L., Luo, J. and Elledge, S. J. (2007) Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130, 986-988 CrossRef PubMed (Pubitemid 47422308)
24. Kolch, W. and Pitt, A. (2010) Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer 10, 618-629 CrossRef PubMed
25. Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G. and Yang, S. C. (2010) Non small cell lung cancer. J. Natl. Compr. Cancer Netw. 8, 740-801
26. Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M. and Boyle, P. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581-592 CrossRef PubMed (Pubitemid 46359643)
27. Ciardiello, F. and Tortora, G. (2008) Drug therapy: EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174 CrossRef PubMed
28. Nair, P. (2005) Epidermal growth factor receptor family and its role in cancer progression. Curr. Sci. 88, 890-898
29. Mellinghoff, I. K., Cloughesy, T. F. and Mischel, P. S. (2007) PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 13, 378-381 CrossRef PubMed (Pubitemid 46225339)
30. Yamazaki, H., Kijima, H., Ohnishi, Y., Abe, Y., Oshika, Y., Tsuchida, T., Tokunaga, T., Tsugu, A., Ueyama, Y. and Tamaoki, N. (1998) Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J. Natl. Cancer Inst. 90, 581-587 CrossRef PubMed (Pubitemid 28204801)
31. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 CrossRef PubMed (Pubitemid 38637993)
32. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V. and Fulton, L. (2004) EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 101, 13306-13311 CrossRef PubMed (Pubitemid 39209661)
33. Tartarone, A., Lazzari, C., Lerose, R., Conteduca, V., Improta, G., Zupa, A., Bulotta, A., Aieta, M. and Gregorc, V. (2013) Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung Cancer 81, 328-336 CrossRef PubMed
34. Wada, H., Mizutani, S., Nishimura, J., Usuki, Y., Kohsaki, M., Komai, M., Kaneko, H., Sakamoto, S., Delia, D., Kanamaru, A. and Kakishita, E. (1995) Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein. Cancer Res. 55, 3192-3196 PubMed
35. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R. and Kantarjian, H. M. (1999) Mechanisms of disease - the biology of chronic myeloid leukemia. N. Engl. J. Med. 341, 164-172 CrossRef PubMed (Pubitemid 29325745)
36. Nowell, P. C. and Hungerford, D. A. (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497-1497
37. Daley, G. Q., Vanetten, R. A. and Baltimore, D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 CrossRef PubMed
38. Deininger, M. W. N., Goldman, J. M. and Melo, J. V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356 PubMed
39. Pluk, H., Dorey, K. and Superti-Furga, G. (2002) Autoinhibition of c-Abl. Cell 108, 247-259 CrossRef PubMed (Pubitemid 34161144)
40. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. and Sawyers, C. L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 CrossRef PubMed (Pubitemid 32267972)
41. Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R. and Scapozza, L. (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4, 75-85 CrossRef PubMed (Pubitemid 36196725)
42. Druker, B. J. (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808-4817 CrossRef PubMed
43. Raab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G. and Anderson, K. C. (2009) Multiple myeloma. Lancet 374, 324-339 CrossRef PubMed
44. Eisenbeis, C. F., Singh, H. and Storb, U. (1995) Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev. 9, 1377-1387 CrossRef PubMed
45. Fire, A., Xu, S. Q., Montgomery, M. K., Kostas, S. A., Driver, S. E. and Mello, C. C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 CrossRef PubMed (Pubitemid 28099681)
46. Baulcombe, D. C. (1996) RNA as a target and an initiator of post-transcriptional gene silencing in transgenic plants. Plant Mol. Biol. 32, 79-88 CrossRef PubMed
47. Bernards, R. (2006) [The Nobel Prize in Physiology or Medicine for 2006 for the discovery of RNA interference]. Ned. Tijdschr. Geneeskd. 150, 2849-2853 PubMed
48. Wilson, R. C. and Doudna, J. A. (2013) Molecular mechanisms of RNA interference. Annu. Rev. Biophys. 42, 217-239 CrossRef PubMed
49. Obbard, D. J., Gordon, K. H., Buck, A. H. and Jiggins, F. M. (2009) The evolution of RNAi as a defence against viruses and transposable elements. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364, 99-115 CrossRef PubMed
50. Carthew, R. W. (2006) Gene regulation by microRNAs. Curr. Opin. Genet. Dev. 16, 203-208 CrossRef PubMed
51. Lund, E. and Dahlberg, J. E. (2006) Substrate selectivity of exportin 5 and Dicer in the biogenesis of microRNAs. Cold Spring Harb. Symp. Quant. Biol. 71, 59-66 CrossRef PubMed
52. Macfarlane, L. A. and Murphy, P. R. (2010) MicroRNA: biogenesis, function and role in cancer. Curr. Genomics 11, 537-561 CrossRef PubMed
53. Esquela-Kerscher, A. and Slack, F. J. (2006) Oncomirs - microRNAs with a role in cancer. Nature Rev. Cancer 6, 259-269 CrossRef
54. Latterich, M. (2008) RNAi, Taylor & Francis Group, New York
55. Boehm, J. S., Zhao, J. J., Yao, J., Kim, S. Y., Firestein, R., Dunn, I. F., Sjostrom, S. K., Garraway, L. A., Weremowicz, S., Richardson, A. L. et al. (2007) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129, 1065-1079 CrossRef PubMed (Pubitemid 46891036)
56. Wohlbold, L., van der Kuip, H., Miething, C., Vornlocher, H. P., Knabbe, C., Duyster, J. and Aulitzky, W. E. (2003) Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102, 2236-2239 CrossRef PubMed (Pubitemid 37122404)
57. Vasconcelos, M. H., Lima, R. T. and Guimarães, J. E. (2007) Overcoming K562Dox resistance to STI571 (Gleevec) by downregulation of P-gp expression using siRNAs. Cancer Ther. 5, 67-76
58. Lee, J. M., Yoon, T. J. and Cho, Y. S. (2013) Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed. Res. Int. 2013, 782041 PubMed
59. Castanotto, D. and Rossi, J. J. (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457, 426-433 CrossRef PubMed
60. Heilbronn, R. and Weger, S. (2010) Viral vectors for gene transfer: current status of gene therapeutics. Handb. Exp. Pharmacol. 197, 143-170 CrossRef PubMed
61. Campos, S. K. and Barry, M. A. (2007) Current advances and future challenges in adenoviral vector biology and targeting. Curr. Gene Ther. 7, 189-204 CrossRef PubMed (Pubitemid 46902201)
62. Shen, C., Buck, A. K., Liu, X., Winkler, M. and Reske, S. N. (2003) Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 539, 111-114 CrossRef PubMed (Pubitemid 36351297)
63. Liu, Q. and Muruve, D. A. (2003) Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 10, 935-940 CrossRef PubMed (Pubitemid 36722427)
64. Hartman, Z. C., Appledorn, D. M. and Amalfitano, A. (2008) Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 132, 1-14 CrossRef PubMed (Pubitemid 351232078)
65. Marshall, E. (1999) Gene therapy death prompts review of adenovirus vector. Science 286, 2244-2245 CrossRef PubMed
66. Yang, Y., Greenough, K. and Wilson, J. M. (1996) Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3, 412-420 PubMed (Pubitemid 26171339)
67. Wonganan, P. and Croyle, M. A. (2010) PEGylated adenoviruses: from mice to monkeys. Viruses 2, 468-502 CrossRef PubMed
68. Wan, Y., Han, J., Fan, G., Zhang, Z., Gong, T. and Sun, X. (2013) Enzyme-responsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity. Biomaterials 34, 3020-3030 CrossRef PubMed
69. Sakuma, T., Barry, M. A. and Ikeda, Y. (2012) Lentiviral vectors: basic to translational. Biochem. J. 443, 603-618 CrossRef PubMed
70. Burnett, J. C., Rossi, J. J. and Tiemann, K. (2011) Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6, 1130-1146 CrossRef PubMed
71. DiGiusto, D. L., Krishnan, A., Li, L., Li, H., Li, S., Rao, A., Mi, S., Yam, P., Stinson, S., Kalos, M. et al. (2010) RNA-based gene therapy for HIV with lentiviral vector-modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2, 36ra43 CrossRef PubMed
72. Yi, Y., Hahm, S. H. and Lee, K. H. (2005) Retroviral gene therapy: safety issues and possible solutions. Curr. Gene Ther. 5, 25-35 CrossRef PubMed (Pubitemid 40246740)
73. Hong, Y., Macnab, S., Lambert, L. A., Turner, A. J., Whitehouse, A. and Usmani, B. A. (2011) Herpesvirus saimiri-based endothelin-converting enzyme-1 shRNA expression decreases prostate cancer cell invasion and migration. Int. J. Cancer 129, 586-598 CrossRef PubMed
74. Smollich, M., Gotte, M., Yip, G. W., Yong, E. S., Kersting, C., Fischgrabe, J., Radke, I., Kiesel, L. and Wulfing, P. (2007) On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res. Treat. 106, 361-369 CrossRef PubMed (Pubitemid 350029691)
75. Wood, M. J. A., Byrnes, A. P., Pfaff, D. W., Rabkin, S. D. and Charlton, H. M. (1994) Inflammatory effects of gene-transfer into the CNS with defective Hsv-1 vectors. Gene Ther. 1, 283-291 PubMed
76. McMenamin, M. M., Byrnes, A. P., Charlton, H. M., Coffin, R. S., Latchman, D. S. and Wood, M. J. (1998) A γ34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience 83, 1225-1237 CrossRef PubMed (Pubitemid 28114213)
77. Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R. and Tsourkas, A. (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338, 903-910 CrossRef PubMed
78. Choi, H. S., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G. and Frangioni, J. V. (2007) Renal clearance of quantum dots. Nat. Biotechnol. 25, 1165-1170 CrossRef PubMed (Pubitemid 47538116)
79. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs1. Cancer Res. 46, 6387-6392 PubMed (Pubitemid 17221789)
80. Tabata, T., Murakami, Y. and Ikada, Y. (1998) Tumor accumulation of poly(vinyl alcohol) of different sizes after intravenous injection. J. Control. Release 50, 123-133 CrossRef PubMed (Pubitemid 28044107)
81. Zhang, Y., Yang, M., Portney, N. G., Cui, D., Budak, G., Ozbay, E., Ozkan, M. and Ozkan, C. S. (2008) Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed. Microdevices 10, 321-328 CrossRef PubMed
82. Bondar, O. V., Saifullina, D. V., Shakhmaeva, I. I., Mavlyutova, I. I. and Abdullin, T. I. (2012) Monitoring of the zeta potential of human cells upon reduction in their viability and interaction with polymers. Acta Naturae 4, 78-81 PubMed
83. Zahr, A. S., Davis, C. A. and Pishko, M. V. (2006) Macrophage uptake of coreshell nanoparticles surface modified with poly(ethylene glycol). Langmuir 22, 8178-8185 CrossRef PubMed (Pubitemid 44412575)
84. Knop, K., Hoogenboom, R., Fischer, D. and Schubert, U. S. (2010) Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49, 6288-6308 CrossRef PubMed
85. Bunka, D. H. J. and Stockley, P. G. (2012) Chapter 6 Therapeutic applications of nucleic acid aptamer conjugates. In DNA Conjugates and Sensors (Fox, K. R. and Brown, T., eds), pp. 140-165, Royal Society of Chemistry, London CrossRef
86. Bareford, L. M. and Swaan, P. W. (2007) Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59, 748-758 CrossRef PubMed (Pubitemid 47320813)
87. Behr, J. P. (1997) The proton sponge - a trick to enter cells the viruses did not exploit. Chimia 51, 34-36
88. Mastico, R. A., Talbot, S. J. and Stockley, P. G. (1993) Multiple presentation of foreign peptides on the surface of an RNA-free spherical bacteriophage capsid. J. Gen. Virol. 74, 541-548 CrossRef PubMed (Pubitemid 23113357)
89. Wu, M., Brown, W. L. and Stockley, P. G. (1995) Cell-specific delivery of bacteriophage-encapsidated ricin A chain. Bioconjug. Chem. 6, 587-595 CrossRef PubMed
90. Galaway, F. A. and Stockley, P. G. (2013) MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform. Mol. Pharm. 10, 59-68 CrossRef PubMed
91. Ashley, C. E., Carnes, E. C., Phillips, G. K., Durfee, P. N., Buley, M. D., Lino, C. A., Padilla, D. P., Phillips, B., Carter, M. B., Willman, C. L. et al. (2011) Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano. 5, 5729-5745 CrossRef PubMed
92. Steinmetz, N. F. and Manchester, M. (2009) PEGylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo. Biomacromolecules 10, 784-792 CrossRef PubMed
93. Strauss, Jr, J. H. and Sinsheimer, R. L. (1963) Purification and properties of bacteriophage MS2 and of its ribonucleic acid. J. Mol. Biol. 7, 43-54 CrossRef PubMed
94. Pang, L., Nowostawska, U., Ryan, J. N., Williamson, W. M., Walshe, G. and Hunter, K. A. (2009) Modifying the surface charge of pathogen-sized microspheres for studying pathogen transport in groundwater. J. Environ. Qual. 38, 2210-2217 CrossRef PubMed
95. Masaki, T., Shiratori, Y., Rengifo, W., Igarashi, K., Yamagata, M., Kurokohchi, K., Uchida, N., Miyauchi, Y., Yoshiji, H., Watanabe, S. et al. (2003) Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37, 534-543 CrossRef PubMed (Pubitemid 36258774)
96. Lo, A., Lin, C. T. and Wu, H. C. (2008) Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol. Cancer Therap. 7, 579-589 CrossRef (Pubitemid 351482141)
97. Greaves, M. (2013) Return of the malingering mutants. Br. J. Cancer 109, 1391-1393 CrossRef PubMed
98. Pan, Y., Jia, T., Zhang, Y., Zhang, K., Zhang, R., Li, J. and Wang, L. (2012) MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. Int. J. Nanomed. 7, 5957-5967 CrossRef
99. Pan, Y., Zhang, Y., Jia, T., Zhang, K., Li, J. and Wang, L. (2012) Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. FEBS J. 279, 1198-1208 CrossRef PubMed
100. Li, J., Sun, Y., Jia, T., Zhang, R., Zhang, K. and Wang, L. (2014) Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer. Int. J. Cancer 134, 1683-1694 CrossRef PubMed
101. Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M. and Danielsen, M. (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A. 84, 7413-7417 CrossRef PubMed
102. Yitbarek, E. (2011) Characterization and Analytical Applications of Dye-Encapsulated Zwitterionic Liposomes. Ph.D. Thesis, North Carolina State University, Raleigh, N.C., U.S.A.
103. Kim, H. K., Davaa, E., Myung, C. S. and Park, J. S. (2010) Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int. J. Pharm. 392, 141-147 CrossRef PubMed
104. Gao, X. and Huang, L. (1995) Cationic liposome-mediated gene transfer. Gene Ther. 2, 710-722 PubMed (Pubitemid 26043284)
105. Kim, H. R., Kim, I. K., Bae, K. H., Lee, S. H., Lee, Y. and Park, T. G. (2008) Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol. Pharm. 5, 622-631 CrossRef PubMed
106. Gabizon, A. and Papahadjopoulos, D. (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U.S.A. 85, 6949-6953 CrossRef PubMed
107. Senior, J., Delgado, C., Fisher, D., Tilcock, C. and Gregoriadis, G. (1991) Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. Biochim. Biophys. Acta 1062, 77-82 CrossRef PubMed
108. Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J. et al. (2013) Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570-1578 CrossRef PubMed
109. Laouini, A., Jaafar-Maalej, C., Limayem-Blouza, I., Sfar, S., Charcosset, C. and Fessi, H. (2012) Preparation, characterization and applications of liposomes: state of the art. J. Colloid Sci. Biotechnol. 1, 147-168 CrossRef
110. Dalby, B., Cates, S., Harris, A., Ohki, E. C., Tilkins, M. L., Price, P. J. and Ciccarone, V. C. (2004) Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 33, 95-103 CrossRef PubMed (Pubitemid 38569654)
111. Baker, B. E., Kestler, D. P. and Ichiki, A. T. (2006) Effects of siRNAs in combination with Gleevec on K-562 cell proliferation and Bcr-Abl expression. J. Biomed. Sci. 13, 499-507 CrossRef PubMed
112. Bjorge, J. D., Pang, A. S., Funnell, M., Chen, K. Y., Diaz, R., Magliocco, A. M. and Fujita, D. J. (2011) Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line. PLoS ONE 6, e19309 CrossRef PubMed
113. Bouchie, A. (2012) Companies in footrace to deliver RNAi. Nat. Biotechnol. 30, 1154-1157 CrossRef PubMed
114. Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M. et al. (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3, 406-417 CrossRef PubMed
115. Chang, H. I. and Yeh, M. K. (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine 7, 49-60 PubMed
116. Davis, M. E. and Brewster, M. E. (2004) Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 3, 1023-1035 CrossRef PubMed (Pubitemid 39642365)
117. Heidel, J. D. and Schluep, T. (2012) Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. J. Drug Deliv. 2012, 262731 CrossRef PubMed
118. Bellocq, N. C., Davis, M. E., Engler, H., Jensen, G. S., Liu, A., Machemer, T., Maneval, D. C., Quijano, E., Pun, S. H., Schluep, T. and Wen, S. (2003) Transferrin-targeted, cyclodextrin polycation-based gene vector for systemic delivery. Mol. Ther. 7, S290 CrossRef
119. Heidel, J. D., Yu, Z., Liu, J. Y., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J. and Davis, M. E. (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. U.S.A. 104, 5715-5721 CrossRef PubMed (Pubitemid 47175600)
120. Pun, S. H. and Davis, M. E. (2002) Development of a non-viral gene delivery vehicle for systemic application. Bioconjug. Chem. 13, 630-639 CrossRef PubMed
121. Bartlett, D. W. and Davis, M. E. (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug. Chem. 18, 456-468 CrossRef PubMed (Pubitemid 46493517)
122. Davis, M. E. (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6, 659-668 CrossRef PubMed
123. Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E. and Triche, T. J. (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992 CrossRef PubMed (Pubitemid 41377390)
124. Cerqueira, N. M., Fernandes, P. A. and Ramos, M. J. (2007) Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat. Anticancer Drug Discov. 2, 11-29 CrossRef PubMed
125. Davis, M. E., Zuckerman, J. E., Choi, C. H., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D. and Ribas, A. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 CrossRef PubMed
126. Czauderna, F., Fechtner, M., Dames, S., Aygun, H., Klippel, A., Pronk, G. J., Giese, K. and Kaufmann, J. (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705-2716 CrossRef PubMed (Pubitemid 37442115)
127. Chiu, Y. L. and Rana, T. M. (2003) siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034-1048 CrossRef PubMed
128. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 CrossRef PubMed (Pubitemid 39545841)
129. Kenski, D. M., Butora, G., Willingham, A. T., Cooper, A. J., Fu, W., Qi, N., Soriano, F., Davies, I. W. and Flanagan, W. M. (2012) siRNA-optimized modifications for enhanced in vivo activity. Mol. Ther. Nucleic Acids 1, e5 CrossRef PubMed
130. Robbins, M., Judge, A., Liang, L., McClintock, K., Yaworski, E. and MacLachlan, I. (2007) 2′-O-Methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 15, 1663-1669 CrossRef PubMed (Pubitemid 47289010)
131. Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K. et al. (2006) Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12, 1197-1205 CrossRef PubMed (Pubitemid 43990545)
132. Bramsen, J. B. and Kjems, J. (2012) Development of therapeutic-grade small interfering RNAs by chemical engineering. Front. Genetics 3, 154 CrossRef
133. Bramsen, J. B., Laursen, M. B., Nielsen, A. F., Hansen, T. B., Bus, C., Langkjaer, N., Babu, B. R., Hojland, T., Abramov, M., Van Aerschot, A. et al. (2009) A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 37, 2867-2881 CrossRef PubMed
134. Glud, S. Z., Bramsen, J. B., Dagnaes-Hansen, F., Wengel, J., Howard, K. A., Nyengaard, J. R. and Kjems, J. (2009) Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides 19, 163-168 CrossRef PubMed
135. Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A. et al. (2005) Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270 CrossRef PubMed (Pubitemid 40460553)
136. Bramsen, J. B., Laursen, M. B., Damgaard, C. K., Lena, S. W., Babu, B. R., Wengel, J. and Kjems, J. (2007) Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res. 35, 5886-5897 CrossRef PubMed (Pubitemid 47506303)
137. Langkjaer, N., Pasternak, A. and Wengel, J. (2009) UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg. Med. Chem. 17, 5420-5425 CrossRef PubMed
138. Bramsen, J. B., Pakula, M. M., Hansen, T. B., Bus, C., Langkjaer, N., Odadzic, D., Smicius, R., Wengel, S. L., Chattopadhyaya, J., Engels, J. W. et al. (2010) A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res. 38, 5761-5773 CrossRef PubMed
139. Laursen, M. B., Pakula, M. M., Gao, S., Fluiter, K., Mook, O. R., Baas, F., Langklaer, N., Wengel, S. L., Wengel, J., Kjems, J. and Bramsen, J. B. (2010) Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol. Biosyst. 6, 862-870 CrossRef PubMed
140. Ellington, A. D. and Szostak, J. W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822 CrossRef PubMed
141. Dey, A. K., Griffiths, C., Lea, S. M. and James, W. (2005) Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA 11, 873-884 CrossRef PubMed (Pubitemid 40994198)
142. McNamara, 2nd, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A. and Giangrande, P. H. (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005-1015 CrossRef PubMed (Pubitemid 44215395)
143. Dassie, J. P., Liu, X. Y., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, 2nd, J. O. and Giangrande, P. H. (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27, 839-849 CrossRef PubMed
144. Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J. et al. (2006) 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3, 199-204 CrossRef PubMed
145. Schwarz, D. S., Hutvagner, G., Du, T., Xu, Z., Aronin, N. and Zamore, P. D. (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208 CrossRef PubMed (Pubitemid 37329583)
146. Bartlett, D. W. and Davis, M. E. (2006) Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34, 322-333 CrossRef PubMed (Pubitemid 43160055)
147. Lorenz, C., Hadwiger, P., John, M., Vornlocher, H. P. and Unverzagt, C. (2004) Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 14, 4975-4977 CrossRef PubMed (Pubitemid 39165605)
148. Zhang, J., Zheng, J., Lu, C., Du, Q., Liang, Z. and Xi, Z. (2012) Modification of the siRNA passenger strand by 5-nitroindole dramatically reduces its off-target effects. ChemBioChem 13, 1940-1945 CrossRef PubMed
149. Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F. and Kay, M. A. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 CrossRef PubMed (Pubitemid 44050158)
150. Ahn, M., Witting, S. R., Ruiz, R., Saxena, R. and Morral, N. (2011) Constitutive expression of short hairpin RNA in vivo triggers buildup of mature hairpin molecules. Hum. Gene Ther. 22, 1483-1497 CrossRef PubMed
151. Rolfsson, O., Toropova, K., Morton, V., Francese, S., Basnak, G., Thompson, G. S., Homans, S. W., Ashcroft, A. E., Stonehouse, N. J., Ranson, N. A. and Stockley, P. G. (2008) RNA packing specificity and folding during assembly of the bacteriophage MS2. Comput. Math. Meth. M. 9, 339-349 CrossRef
152. Borodavka, A., Tuma, R. and Stockley, P. G. (2012) Evidence that viral RNAs have evolved for efficient, two-stage packaging. Proc. Natl. Acad. Sci. U.S.A. 109, 15769-15774 CrossRef PubMed
153. Stockley, P. G., Rolfsson, O., Thompson, G. S., Basnak, G., Francese, S., Stonehouse, N. J., Homans, S. W. and Ashcroft, A. E. (2007) A simple, RNA-mediated allosteric switch controls the pathway to formation of a T = 3 viral capsid. J. Mol. Biol. 369, 541-552 CrossRef PubMed (Pubitemid 46678041)
154. Valegard, K., Murray, J. B., Stockley, P. G., Stonehouse, N. J. and Liljas, L. (1994) Crystal structure of an RNA bacteriophage coat protein-operator complex. Nature 371, 623-626 CrossRef PubMed (Pubitemid 24315746)
155. Weinberg, R. A. (2007) The Biology of Cancer, Garland Science, New York
156. Arteaga, C. L. (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7, 31-39 CrossRef PubMed
157. Chen, Y. F., Wang, J. Y., Wu, C. H., Chen, F. M., Cheng, T. L. and Lin, S. R. (2005) Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett. 229, 115-122 CrossRef PubMed
158. Guan, H. Y., Zhang, H., Cai, J. C., Wu, J. H., Yuan, J., Li, J., Huang, Z. S. and Li, M. F. (2011) IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-κ B. J. Pathol. 223, 436-445 CrossRef PubMed
159. Lutterbach, B., Zeng, Q. W., Davis, L. J., Hatch, H., Hang, G. Z., Kohl, N. E., Gibbs, J. B. and Pan, B. S. (2007) Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67, 2081-2088 CrossRef PubMed (Pubitemid 46424226)
160. Yoshida, T., Okamoto, I., Okamoto, W., Hatashita, E., Yamada, Y., Kuwata, K., Nishio, K., Fukuoka, M., Janne, P. A. and Nakagawa, K. (2010) Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci. 101, 167-172 CrossRef PubMed
161. Wilda, M., Fuchs, U., Wossmann, W. and Borkhardt, A. (2002) Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21, 5716-5724 CrossRef PubMed
162. Sharma, S. V. and Settleman, J. (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231 CrossRef PubMed (Pubitemid 350277749)
163. Iida, S., Rao, P. H., Butler, M., Corradini, P., Boccadoro, M., Klein, B., Chaganti, R. S. K. and DallaFavera, R. (1997) Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nature Genet. 17, 226-230 CrossRef
164. Ashwell, S. and Zabludoff, S. (2008) DNA damage detection and repair pathways - recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin. Cancer Res. 14, 4032-4037 CrossRef PubMed
165. Muller, A. J. and Scherle, P. A. (2006) Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer 6, 613-625 CrossRef PubMed R.Y. received financial support from the Leeds University Research Scholarship programme. (Pubitemid 44140859)